Insider Ledger
GALT insider buying and SEC filings, explained
Galectin Therapeutics Inc. · CIK 1133416
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- NV
- Fiscal year end
- Dec 31
- Former names
- PRO PHARMACEUTICALS INC
Insider activity in the last 12 months
Bought
$20K
Insiders who bought
1
Sold (not marked 10b5-1)
$1.3M
Planned sales (10b5-1)
$4.6M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jul 14, 2026 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 16,250 shares at about $5.13 ($83K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jul 16, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Harold H. Shlevin (Director) sold 30,000 shares between Jun 26 and Jun 29 at about $5.03 ($151K), marked as a 10b5-1 plan trade. Holdings down 82% to 6,500 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 26–29, 2026 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 52,037 shares between Jun 26 and Jun 29 at about $5.04 ($262K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 23, 2026 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 7,557 shares at about $3.14 ($24K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jun 25, 2026 |
| May 26, 2026 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 568 shares at about $3.10 ($2K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 28, 2026 |
| Feb 6, 2026 | Purchase (code P) | Kary Eldred (Director) bought 300 shares at $2.70 ($810), reported as a purchase (code P). Holdings up <1% to 65,682 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 9, 2026 |
| Jan 2–6, 2026 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 84,000 shares between Jan 2 and Jan 6 at about $3.83 ($321K), marked as a 10b5-1 plan trade. Holdings down 9% to 832,592 shares. | SEC filing Filed Jan 6, 2026 |
| Jan 2–6, 2026 | Planned (10b5-1) | Jack W. Callicutt (CFO) sold 60,000 shares between Jan 2 and Jan 6 at about $3.89 ($233K), marked as a 10b5-1 plan trade. Holdings down 89% to 7,614 shares. | SEC filing Filed Jan 6, 2026 |
| Jan 2–6, 2026 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 60,000 shares between Jan 2 and Jan 6 at about $3.88 ($233K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 31, 2025 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 8,125 shares at about $4.07 ($33K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 23, 2025 | Purchase (code P) Amended filing | Kevin D. Freeman (Director) bought 5,500 shares at $3.55 ($20K), reported as a purchase (code P). Holdings up 11% to 55,269 shares. Not marked as a 10b5-1 plan trade. This amends a filing from Dec 23, 2025. | SEC filing Filed Dec 23, 2025 |
| Dec 23, 2025 | Purchase (code P) | Kary Eldred (Director) bought 700 shares at $3.73 ($3K), reported as a purchase (code P). Holdings up 1% to 65,382 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 23, 2025 |
| Dec 23, 2025 | Purchase (code P) | Kary Eldred (Director) bought 700 shares at $3.73 ($3K), reported as a purchase (code P). Holdings up 1% to 65,382 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 17, 2025 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 7,829 shares at about $7.06 ($55K), marked as a 10b5-1 plan trade. Holdings down 1% to 832,592 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 17, 2025 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 19,442 shares at about $7.04 ($137K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 17, 2025 | Planned (10b5-1) | Harold H. Shlevin (Director) sold 24,499 shares at about $7.04 ($172K), marked as a 10b5-1 plan trade. Holdings down 79% to 6,500 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 16, 2025 | Sale | James C. Czirr (10% owner) sold 30,681 shares at about $6.66 ($204K). Holdings down 1% to 5,614,457 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. | SEC filing Filed Dec 18, 2025 |
| Dec 12–15, 2025 | Planned (10b5-1) | Harold H. Shlevin (Director) sold 28,210 shares between Dec 12, 2025 and Dec 15, 2025 at about $6.28 ($177K), marked as a 10b5-1 plan trade. Holdings down 72% to 11,206 shares. | SEC filing Filed Dec 16, 2025 |
| Dec 8–9, 2025 | Planned (10b5-1) | Harold H. Shlevin (Director) sold 175,790 shares between Dec 8, 2025 and Dec 9, 2025 at about $6.00 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 94% to 11,206 shares. | SEC filing Filed Dec 10, 2025 |
| Dec 2–3, 2025 | Sale Amended filing | James C. Czirr (10% owner) sold 162,069 shares between Dec 2, 2025 and Dec 3, 2025 at about $5.68 ($921K). Holdings down 3% to 5,670,138 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. This amends a filing from Dec 4, 2025. | SEC filing Filed Dec 8, 2025 |
| Nov 17–18, 2025 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 22,463 shares between Nov 17, 2025 and Nov 18, 2025 at about $6.07 ($136K), marked as a 10b5-1 plan trade. Holdings down 3% to 832,592 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 17–18, 2025 | Planned (10b5-1) | Jack W. Callicutt (CFO) sold 77,920 shares between Nov 17, 2025 and Nov 18, 2025 at about $6.14 ($479K), marked as a 10b5-1 plan trade. Holdings down 91% to 7,614 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | Khurram Jamil (Chief Medical Officer) sold 121,117 shares at about $5.47 ($663K), marked as a 10b5-1 plan trade. Holdings down 96% to 4,479 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 11, 2025 | Sale | James C. Czirr (10% owner) sold 40,000 shares at $5.25 ($210K). Holdings down 1% to 5,832,207 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 2 other reporting owners. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Jack W. Callicutt (CFO) sold 5,291 shares at about $6.03 ($32K), marked as a 10b5-1 plan trade. Holdings down 41% to 7,614 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 10, 2025 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 1,867 shares at about $6.03 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 832,592 shares. | SEC filing Filed Nov 12, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 200 shares at $6.00 ($1K), marked as a 10b5-1 plan trade. Holdings down <1% to 832,592 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 5, 2025 | Planned (10b5-1) | Jack W. Callicutt (CFO) sold 600 shares at $6.00 ($4K), marked as a 10b5-1 plan trade. Holdings down 7% to 7,614 shares. | SEC filing Filed Nov 7, 2025 |
| Nov 3–4, 2025 | Planned (10b5-1) | Joel Lewis (CEO and Director) sold 15,720 shares between Nov 3, 2025 and Nov 4, 2025 at about $6.07 ($95K), marked as a 10b5-1 plan trade. Holdings down 2% to 832,592 shares. | SEC filing Filed Nov 5, 2025 |
| Nov 3–4, 2025 | Planned (10b5-1) | Jack W. Callicutt (CFO) sold 32,439 shares in 2 share classes between Nov 3, 2025 and Nov 4, 2025 at about $6.06 ($197K), marked as a 10b5-1 plan trade. Holdings of Common Stock down 80% to 7,614 shares. | SEC filing Filed Nov 5, 2025 |
39 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow GALT in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.